kstew call note management reaffirm lrp expect
tuck-in larger deal
morn
share versu et surpris reaction stock
better-than-expect result higher guidanc view move appropri note publish morn
first look sale ep better tax help guidanc rais md target remain addit detail result
note morn earn call highlight
medic deliv eri sale guidanc remain year manag note expect see acceler growth second
half need year-to-d basi constant currenc sale flat
expect tuck-in acquisit baxter ceo comment investor think baxter ad valu small tuck-in
baxter look right opportun valuat larger deal comment valuat rich right
market frothi note manag would compromis return expect moreov note larger
deal greater inher risk price valuat whack inher risk enorm
invest asset price valuat whack one cant make intern rate return low
renal outlook giv en executiv order baxter manag view longer term posit manag comment
analyz potenti impact would comment final rule said manag note would make
capit invest million support growth periton dialysi pd busi
lrp reaffirm ed ask whether posit news flow develop could lead higher lrp baxter manag
re-affirmed long-rang plan manag comment alway put take posit
earlier myxredlin approv expect end year approv momentum pd busi also
note sinc last time gave guidanc dynam medic deliveri busi shift reconfirm lt
expect despit manag said earli start think chang lrp
pleas reach via email question
baxter maintain posit trajectori sale grow th constant currenc oper basi ep ere exceed
expect y/i grow th driven top line oper effici low er tax rate low er share count
constant currenc basi global grow th renal driven increas volum pd product result ere neg impact
strateg exit us hd center busi also impact recal manufactur challeng produc revaclear hemo
dialyz temporari suppli constraint slow ing dow product line ramp expect increment cost
recent advanc kidney initi announc hite hous propos ould transform impact
end stage renal diseas esrd us part emerg trend orldw ide payor clinician patient increasingli
embrac home pd frontlin esrd treatment option base key econom therapeut lifestyl benefit baxter
global market leader home pd anticip capit invest significantli increas product capac meet
need line ith propos model invest ill scale align ith patient market dynam increas
demand ould help acceler renal grow th contribut posit baxter previous commun financi estim
 ork model anticip impact expect better posit provid addit inform final
later year
medic deliveri return solid constant currenc grow th global grow th benefit new infus pump us
select intern market relat dispos minibag lvp intern contribut grow th
mid-singl digit grow th pharma driven hospit compound baxter ahmedabad busi offset brevi cyclo gener
pharma remain key grow th driver compani benefit new product launch includ recent approv
clinic nutrit low singl digit sale grow th build momentum part ith new product posit us launch clini-lipid
advanc surgeri high teen grow th cc rate benefit competit suppli constraint benefit floseal recothrom
acut therapi high singl digit constant currenc grow th part due prismax roll-out crrt
continu see baxter renew ed emphasi innov great promis potenti ahead importantli
employe ho inspir empow ere
constant currenc grow th across busi unit reinforc confid outlook
sale billion flat report basi constant currenc oper basi strength across portfolio
adjust ep exceed guidanc driven top line on-going op effici low er tax rate
note constant currenc cc oper sale growth except pharmaceut busi america region
america grew cc basi oper emea cc basi asia-pac cc basi
renal sale ere cc basi perform driven hsd pd global partial offset low er sale select in-
enter hd product includ blood line exit earlier year impact renal care also impact recal suppli
constraint associ dialyz
medic dleiveri sale ere cc return solid balanc grow th us ou perform benefit
strength infus system spectrumiq evoiq lvp latin america momentum minibag plu
pharmaceut sale ere cc oper strong ou contribut perform driven hospit
pharmaci compound gener inject clari anesthesia declin us low er sale brevi cyclo sale us
impact low er anesthesia critic care product
nutrit sale cc basi reflect sequenti improv us ou expect sale ramp throughout
 ork rebuild us busi capit new product launch
advanc surgeri sale ere cc basi strong global grow th abil address competitor suppli constraint
ad grow th quarter
acut therapi sale ere cc basi grow th normal difficult comp global grow th driven
 hich includ contract manufactur dow cc basi reflect challeng comp prior year
gross margin repres declin continu benefit manufactur improv portfolio initi
 off-set low er brevi cyclo less favor product mix gross margin also impact expens enhanc
manufactur facil dialyz
sg dow report cc basi reflect posit contribut target initi improv oper effici
invest hile maintain focu drive increas effect
 expens dow report basi cc basi benefit effici hile priorit strateg
op margin y/i
net interest driven low er interest incom increas interest expens issu new euro debt averag
coupon yr durat
driven pension benefit fx gain balanc sheet posit
tax rate quarter benefit tax rule along ith stock comp deduct
adjust ep exceed guidanc
repurchas share off-set option relat dilut
 line ith expect sequenti improv dio cash convers
expect sale grow th constant currenc oper basi
renal grow th expect prior strong grow th pd off-set low er in-cent hd due strateg
exit us blood line hich impact sale addit suppli disrupt revaclear hich impact
expect return normal inventori level end year
medic deliveri sale still expect grow th approx ith sequenti improv
pharma expect low singl digit constant currenc basi prior low singl digit declin cyclo versu prior
assumpt adjust cyclo oper msd increas breviblock includ op grow th declin
advanc surgeri expect high singl digit increas given ytd assum competit suppli constrain eas prior
guidanc grow th
busi expect sale declin low mid-singl digit consist ith prior
adj op margin expans ith addit save oper off-set gm impact return dialyz plant full capac
year end hich increment expens
net interest expect
adjust incom
year expect averag tax rate reflect favor
expect dilut share count
continu expect ocf
expect sale grow th report basi grow th constant currenc oper basi
adjust ep
 question manag respons verbatim
medic deliv eri aintain guidanc feel arket stabil busi predict
tough comp confid secur current custom sign gpo agreement great number idn market
stabl opportun gain custom acut care market also oem/contract manufactur busi ell pump
healthi pipelin alw ay pluse minus pluse inning new manag group put us done
extraordinari drive pipelin creation valu new pump best-in-class drug librari busi predict
healthi continu make progress continu sourc invest new pump platform come along extrem ell
guidanc floseal benefit assum ption comment upsid dont like forecast competitor
outag dont maintain assumpt visibl resumpt ill factor baxter count month
addit benefit count anyth
myxredlin new product read-to-us insulin iv infus assum ption orkhors product hospit estim
market hospit us viabl long term opportun baxter singl digit million base guidanc
point meaning impact year tune guidanc meaning impact
 perform anc im pressiv off-set lower gross argin lower sg take hit
sg com ing rapidli com ent gross margin littl expect relat busi
mix strong perform drug compound that low er margin corpor average high low er gm
margin address dialyz manufactur issu that impact quarter abl off-set ith focu
spend sg side focus improv effici back offic oper judici spend everi dollar littl
differ relat time get infrastructur cost faster new product spend ill see tick
 ant invest grow fund program success hold back dollar spirit innov quarter
tune back half hole thing creat effici line spend differ
 spend spend money invest opportun medic deliveri acut renal care point care
pd advanc surgeri nutrit arbitrag labor ith oper around globe
capit deploym ent surpris edtech aluat balanc
 aluat stock com pani aluat busi first half analyz opportun focu area monitor
acut renal care critic care also focus look individu molecul almeida comment investor think
baxter ad valu ith small tuck-in baxter look right opportun valuat larger deal
rich right market frothi go compromis return larger inher risk enorm
invest asset price valuat hack cant make irr low singl digit doesnt
 ork anyth goe rong like fda doesnt like someth hole valuat target scrutini
care understand target much opportun base busi opportun innov
busi atch baxter pump busi come ith great pump let add inorgan tuck-
baxter continu acquir share prudent go sit cash manag said ont let cash
burn hole baxter pocket
put solid pipelin ake good progress hav som new structur tailwind think factor
suggest upward pressur long rang plan off-set headwind think long rang plan hen give year
plan alw ay put take best intent orld didnt plan insulin premix approv earli
 tow ard end year thing ork ay ell look major forc
momentum pd busi term patient grow th experienc healthi grow th term patient ithout execut
order come becom rule experienc high singl digit grow th patient pd offset neg
futur betw een everyth happen market thing baxter manag reconfirm long rang plan
sinc gain long rang guidanc ost news flow positiv negativ es hav pop
ake ore concern last time gave guidanc dynam medic deliveri busi shift reconfirm
long term expect despit strength area portfolio pipelin progress ith pd manag think
earli start chang lrp point balanc pleas ith quarter pleas ith oper strength longer term
good piec new add de-risk stori
renal busi youv face headwind exit in-cent hd busi annual
inv estm ent benefit pressur gross argin ith respect blood line that one compon hd
busi us product sell product distribut low margin impact sale year
end year done ceas headw ind end year invest best abil scope project
base inform esrd new final rule comment complet soon hh put rule place
base hat know execut order suppli market ith grow th project period clinic given
opportun chang pattern betw een clinic home therapi accommod ith suppli chain reorgan ell
re-regist product small invest modest part give increment capac also new
plant program feel moral respons custom opportun
ep guidanc factor keep mind dialyz impact ill impact tax rate
 ill see uplift tax rate that mask strong oper perform dont expect
see benefit tax rate tax rate pick ish
pharm despit headwind well cant com better solid perform driven compound
busi ou grew move dont expect see level acceler perform
driver take grow th dow pleas ith perform great sourc grow th ith thing like myxredlin clari
portfolio solid perform
infus system one com petitor issu pum infus set opportun new pum
platform com ing custom er wait opportun mostli relat strength version pump
oper drug librari exist custom renew ing like innov product there alw ay opportun hen
problem ith competitor market problem perceiv perman temporari look advanc
surgeri that temporari gain competitor come back product good floseal best market
opportun retain account appli infus pump depend perman issu success
good sale effort new team complet focus pipelin abil demonstr drug librari better
custom need product take lvp pump hat today gut new pump differ
modern ill horizont pump orkflow drug librari featur new product ith oper great
pump mechan great pump version oper custom lot gain ith pump hich
famili custom see need pump noth lose buy bring market syring
pca ell month first one ambulatori busi postpon today
asia pacif strong what driv ing pleas ith grow th ith strength across board solid perform china
plu surpris base histor commentari tremend perform japan high singl digit grow th
combin factor play solid se asia great australia new zeland doubl digit grow th benefit compound
kayugua see momentum patient addit full year basi expect come dow littl bit overal great
perform
pharm aceut busi what updat busi warn letter believ busi start take
shape baxter second none formul team start long pipelin baxter ahmedabad legaci clari
manag hat said fda provid ith feedback de-risk opportun futur
altern suppli almost anyth make also futur molecul go instead clari
back-up futur one molecul develop also ill pilot illinoi facil hat told fda remedi
 arn letter also everyth de-risk revenu stream perform busi ell doubl digit
grow th us also europ
warn letter resolut tim ing im pact acceler develop molecul think off-set neg
potenti cant rate like like plan happen get clearanc ould great
postpon baxter back-up plan ill probabl alter trajectori busi there upsid happen
success
renal busi inv estm ent ake expect return execut order signific amount
interpret comment period think today us pd penetr baxter close
market share pd global basi us popul target
demonstr inconceiv think doubl patient period demonstr ithin year period
flex invest
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
